
Opinion|Videos|September 3, 2024
Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Panelists discuss how criteria such as patient comorbidities, disease progression levels, and treatment goals should be considered when selecting the appropriate form of abiraterone for patients with mCRPC, and also explore the potential benefits and drawbacks of using micronized abiraterone in specific patient populations.
Advertisement
Episodes in this series

- In your opinion, what criteria should be considered when selecting the appropriate form of abiraterone for patients with mCRPC?
- What are the potential benefits or drawbacks when using micronized abiraterone in specific patient populations (eg, those with comorbidities or differing levels of disease progression)?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH
2
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
3
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
4
Contextualizing Cretostimogene in the Evolving Treatment Landscape
5








